GABELLI & Co INVESTMENT ADVISERS INC. Invests $1.79 Million in Drugs Made In America Acquisition II Corp. $DMII

GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 179,500 shares of the company’s stock, valued at approximately $1,790,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC acquired a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $265,000. Virtu Financial LLC acquired a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at $317,000. ABC Arbitrage SA purchased a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at $396,000. Deltec Asset Management LLC acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth $495,000. Finally, Royal Bank of Canada acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth $655,000.

Drugs Made In America Acquisition II Trading Up 0.1%

NASDAQ:DMII opened at $10.10 on Friday. Drugs Made In America Acquisition II Corp. has a 12-month low of $9.86 and a 12-month high of $10.11. The company has a 50 day moving average of $10.08.

Wall Street Analysts Forecast Growth

DMII has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.